Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir
Scandinavian Journal of Infectious Diseases · 2013-02 · 45 (2) · 147-154
DOI: 10.3109/00365548.2012.712213 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scandinavian Journal of Infectious Diseases, online erschienen am 19.09.2012. Verfasst von Leonardo Calza und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Geriatrics and Nephrologic Diseases, Alma Mater Studiorum University of Bologna, S. Orsola-Malpighi Hospital, Bologn…. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: We performed a retrospective cohort study of HIV-infected antiretroviral-naïve patients starting a first antiretroviral therapy with tenofovir/emtricitabine plus efavirenz (EFV), atazanavir/ritonavir (ATV/r), or lopinavir/ritonavir (LPV/r). METHODS: The incidence of renal impairment or proximal tubular dysfunction was evaluated during a 12-month follow-up. Renal impairment was diagnosed by a reduced estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease (MDRD) formula, and tubular dysfunction was diagnosed when ≥ 2 among proteinuria, glucosuria, hypouricaemia, hypophosphataemia, and hypokalaemia, were identified. RESULTS: A total of 235 patients were enrolled: 82 taking EFV, 78 ATV/r, and 75 LPV/r. The mean decline in eGFR after the 12-month follow-up was significantly greater in subjects treated with ATV/r (-10.4 ml/min/1.73 m(2)) than in those receiving EFV (- 5.1; p = 0.002) or LPV/r (-4.8; p = 0.003). Similarly, a significantly higher incidence of proximal tubulopathy was observed among ATV/r-treated patients (14.1%) compared with patients receiving EFV (4.9%) or LPV/r (5.3%). CONCLUSIONS: In our retrospective study, naïve patients receiving tenofovir/emtricitabine and ATV/r for 12 months showed a significantly higher decline in eGFR and a significantly higher incidence of proximal tubulopathy than those receiving tenofovir/emtricitabine plus EFV or LPV/r, even though clinically evident renal toxicity associated with tenofovir-based treatment is a very uncommon event.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Geriatrics and Nephrologic Diseases, Alma Mater Studiorum University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy. leonardo.calza@unibo.it
Zitieren
APA
Calza, L., Trapani, F., Salvadori, C., Magistrelli, E., Manfredi, R., Colangeli, V., Di Bari, M. A., Borderi, M., & Viale, P. (2013). Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir. Scandinavian Journal of Infectious Diseases, 45(2), 147-154. https://doi.org/10.3109/00365548.2012.712213
Vancouver
Calza L, Trapani F, Salvadori C, Magistrelli E, Manfredi R, Colangeli V, et al. Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir. Scandinavian Journal of Infectious Diseases. 2013;45(2):147-154. doi:10.3109/00365548.2012.712213
BibTeX
@article{Calza2013,
author = {Calza, Leonardo and Trapani, Filippo and Salvadori, Caterina and Magistrelli, Eleonora and Manfredi, Roberto and Colangeli, Vincenzo and Di Bari, Maria Assunta and Borderi, Marco and Viale, Pierluigi},
title = {Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir},
journal = {Scandinavian Journal of Infectious Diseases},
year = {2013},
volume = {45},
number = {2},
pages = {147--154},
doi = {10.3109/00365548.2012.712213}
}
EUVIMED